The Drivers of Transnational Subsidiary Evolution: The Upgrading of Process R&D in the Irish Pharmaceutical Industry

Regional Studies

Volumn 46, Issue 9, 2012, Pages 1153-1167

  van Egeraat, Chris ^a   Breathnach, Proinnsias ^a  

^a HIGH ENERGY MATERIALS RESEARCH LABORATORY   (India)

Author keywords

Ireland; Pharmaceutical industry; Research and development (R D); Subsidiary evolution; Transnational corporations

Indexed keywords

ECONOMIC GROWTH; INDUSTRIAL DEVELOPMENT; PHARMACEUTICAL INDUSTRY; RESEARCH AND DEVELOPMENT;

IRELAND;

EID: 84861772892     PISSN: 00343404     EISSN: 13600591     Source Type: Journal    
DOI: 10.1080/00343404.2012.657620     Document Type: Article

References (57)

1. Agrawal, M. 1999. Global Competitiveness in the Pharmaceutical Industry: The Effect of National Regulatory, Economic and Market Factors, New York, NY: Pharmaceutical Products Press.
2. Amin, A. and Tomaney, J. 1995. "The regional development potential of inward investment in the less favoured regions of the European Community". In Behind the Myth of European Union: Prospects for Cohesion, Edited by: Amin, A. and Tomaney, J. 201-220. London: Routledge.
3. Bartlett, C. and Ghoshal, S. 1986. Tap your subsidiaries for global reach. Harvard Business Review, 64(6): 84-87.
4. Bartlett, C. A. and Ghoshal, S. 1989. Managing across Borders: The Transnational Solution, Cambridge, MA: Harvard Business School Press.
5. Birkinshaw, J. and Hood, N. 1998. Multinational subsidiary evolution: capability and charter change in foreign-owned subsidiary companies. Academy of Management Review, 23(4): 773-795.
6. Birkinshaw, J., Hood, N. and Jonsson, S. 1998. Building firm-specific advantages in multinational corporations: the role of subsidiary initiative. Strategic Management Journal, 19: 221-241.
7. Brock, D. 2000. Review of multinational corporate evolution and subsidiary development by Birkinshaw and Hood. Academy of Management Review, 24(1): 259-261.
8. Cantwell, J. and Piscitello, L. 2005. Recent location of foreign-owned research and development activities by large multinational corporations in European regions: the role of spillovers and externalities. Regional Studies, 39(1): 1-16.
9. Cantwell, J. and Mudambi, R. 1998. "The Location of MNE R&D Activity: The Role of Investment Incentives. Discussion Papers in International Investment and Management Series B 250. Department of Economics". Reading: University of Reading.
10. Chiesa, V. 1996. Separating research from development: evidence from the pharmaceutical industry. European Management Journal, 14(6): 638-647.
11. D'Cruz, J. 1986. "Strategic management of subsidiaries". In Managing the Multinational Subsidiary, Edited by: Etemad, H. and Dulude, S. 75-89. London: Croom Helm.
12. Dicken, P. 2007. Global Shift: Mapping the Changing Contours of the World Economy, London: Sage.
13. Dicken, P., Forsgren, M. and Malmberg, A. 1994. "The local embeddedness of transnational corporations". In Globalisation, Institutions and Regional Development in Europe, Edited by: Amin, A. and Thrift, N. 23-45. Oxford: Oxford University Press.
14. Duff, C. 2007. Ireland's Economic Progress, Green Bay, WI: The Taxpayers Network. (available at: http://www.taxpayersnetwork.org) (accessed on 1 December 2010)
15. Duga, J. and Studt, T. 2006. Global R&D report. R&D Magazine, September, 1-17
16. Dunning, J. H. 1995. Re-appraising the eclectic paradigm in an age of alliance capitalism. Journal of International Business Studies, 6(3): 461-491.
17. Eaton, B., Lipsey, R. and Safarian, A. 1994. "The theory of multinational plant location: agglomerations and disagglomerations". In Multinationals in North America, Edited by: Eden, L. 79-102. Calgary, AB: University of Calgary Press.
18. Enterprise Strategy Group. 2004. Ahead of the Curve: Ireland's Place in the Global Economy, Dublin: Forfás.
19. Florida, R. 1997. The globalization of R&D: results of a survey of foreign-affiliated R&D laboratories in the USA. Research Policy, 26: 85-103.
20. Forfás. 2003. The Supply and Demand for Skills in the Biotechnology Industry, Dublin: Forfás.
21. Forsgren, M., Johanson, J. and Sharma, D. 2000. "Development of MNC centres of excellence". In The Emergence and Impact of MNC Centres of Excellence: A Subsidiary Perspective, Edited by: Holm, U. and Pedersen, T. Houndsmills: Macmillan.
22. Frost, T., Birkinshaw, J. and Ensign, P. 2002. Centers of excellence in multinational corporations. Strategic Management Journal, 23(11): 997-1018.
23. Gambardella, A., Orsenigo, L. and Pammolli, F. 2000. Global Competitiveness in Pharmaceuticals: A European Perspective, Brussels: Enterprise Directorate-General of the European Commission.
24. Gereffi, G. 1995. "Global production systems and Third World development". In Global Change, Regional Response: The New International Context of Development, Edited by: Stallings, B. 100-142. Cambridge: Cambridge University Press.
25. Hayter, R. 1998. "Research and development". In The Global Economy in Transition, Edited by: Daniels, P. and Lever, W. 64-190. Harlow: Longman.
26. Hedlund, G. 1986. The hypermodern MNC: a heterarchy. Human Resource Management, 25(Spring): 9-35.
27. Hood, N. and Taggart, J. 1999. Subsidiary development in German and Japanese manufacturing subsidiaries in the British Isles. Regional Studies, 33: 513-528.
28. Howells, J. 1984. The Location of research and development: some observations and evidence from Britain. Regional Studies, 18(1): 13-29.
29. Howells, J., Gagliardi, D. and Malik, K. Strategic sourcing for innovation: organisational and locational issues in the pharmaceuticals sector. Paper presented to workshop on 'Organisational Configurations and Locational Choices of Firms: Responses to Globalisation in Different Industry and Institutional Environments'. April14-152005. University of Cambridge, Cambridge, UK.
30. Irish Council for Science Technology and Innovation (ICSTI). 1999. Technology Foresight Ireland, Dublin: ICSTI.
31. Irish Council for Science Technology and Innovation (ICSTI). 2003. Embedding the Pharmachem Industry in Ireland, Dublin: ICSTI.
32. Kuemmerle, W. 1999. The drivers of foreign direct investment into research and development: an empirical investigation. Journal of International Business Studies, 30: 1-24.
33. Lall, S. 1979. Multinational companies and concentration: the case of the pharmaceutical industry. Social Scientist, 7(8/9): 3-29.
34. Malecki, E. 1997. Technology & Economic Development: The Dynamics of Local, Regional and National Competitiveness, Harlow: Addison Wesley Longman.
35. Mutti, J. and Grubert, H. 2007. The Effect of Taxes on Royalties and the Migration of Intangible Assets Abroad. Working Paper Number W13248, Cambridge, MA: National Bureau of Economic Research (NBER).
36. Patterson, S. and Brock, D. 2002. The development of subsidiary-management research and theoretical analysis. International Business Review, 11: 139-163.
37. Pearce, R. 1992. "Factors Influencing the internationalization of research and development in multinational enterprises". In Multinational Enterprises in the World Economy, Edited by: Buckley, P. and Casson, M. 75-95. Aldershot: Edward Elgar.
38. Pearce, R. 1999b. The evolution of technology in multinational enterprises: the role of creative subsidiaries. International Business Review, 8: 125-148.
39. Pearce, R. D. 1999a. Decentralised R&D and strategic competitiveness: globalised approaches to generation and use of technology in multinational enterprises. Research Policy, 28: 157-178.
40. Pisano, G. 1997. The Development Factory: Unlocking the Potential of Process Innovation, Boston, MA: Harvard Business School Press.
41. Ronstadt, R. 1978. International R&D: the establishment and evolution of research and development abroad by seven US multinationals. Journal of International Business Studies, 9: 7-24.
42. Schmid, S. and Schurig, A. 2003. The development of critical capabilities in foreign subsidiaries: disentangling the role of the subsidiary's business network. International Business Review, 12: 755-782.
43. Schofield, M. 2001. "The global pharmaceutical industry". In Globalisation: The External Pressures, Edited by: Kirkbride, P. 251-284. New York, NY: Wiley.
44. Schweitzer, S. 1997. Pharmaceutical Economics and Policy, New York, NY: Oxford University Press.
45. Science Foundation Ireland (SFI). 2006. Annual Report and Accounts 2005, Dublin: SFI.
46. Simpson, G. 2005. Wearing of the Green: Irish subsidiary lets Microsoft slash taxes in U.S. and Europe. Wall Street Journal, 7 November
47. Tavares, A. 2001. Strategic Management of Multinational Networks: A Subsidiary Evolution Perspective. Discussion Papers in International Investment and Management, Reading: University of Reading.
48. Tavares, A. 2002. Multinational subsidiary evolution and public policy: two tales from the European periphery. Journal of Industry, Competition and Trade, 2(3): 195-213.
49. The Irish Times. 2006. GlaxoSmithKline pays $3.1bn in tax settlement. The Irish Times, 12 September
50. Van Egeraat, C. 2006. The Pharmaceutical Industry in Ireland: Agglomeration, Localisation, or Simply Spatial Concentration. Working Paper Number 28. National Institute for Regional and Spatial Analysis (NIRSA), Maynooth: National University of Ireland.
51. Van Egeraat, C. 2010. The scale and scope of process R&D in the Irish pharmaceutical industry. Irish Geography, 43(1): 35-58.
52. Van Egeraat, C. and Barry, F. 2009. The Irish pharmaceutical industry over the boom period and beyond. Irish Geography, 42(1): 23-44.
53. Van Egeraat, C. and Breathnach, P. 2007. "The manufacturing sector". In Understanding Contemporary Ireland, Edited by: Kitchin, R. and Bartley, B. 125-146. Dublin: Pluto.
54. White, R. and Poynter, T. 1984. Strategies for foreign-owned subsidiaries in Canada. Business Quarterly, 48(4): 59-69.
55. White, P. 2000. "The muscles of the Celtic tiger: IDA's winning sectors'". In The Making of the Celtic Tiger, Edited by: Mac Sharry, R. and White, P. 272-308. Cork: Mercier.
56. Young, S., Hood, N. and Peters, E. 1994. Multinational enterprises and regional economic development. Regional Studies, 28: 657-677.
57. Zanfei, A. 2000. Transnational firms and the changing organisation of innovative activities. Cambridge Journal of Economics, 24: 515-542.